Loading stock data…
DSGN
$13.17-0.13 (-0.98%)
Market ClosedLast close May 4
Design Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Design Therapeutics, Inc. in the Healthcare sector is trading at $13.17. The stock is currently 24% below its 52-week high of $17.25, remaining 56.2% above its 200-day moving average. Technical signals show neutral RSI of 53 and bearish MACD signal, explaining why DSGN maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.17
Potential Upside
5%
Whystock Fair Value$13.83
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platfo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$824.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.84%
Volume
Today's trading volume
404,065
Recent News
Design Therapeutics Inc (DSGN) Q1 2026 Earnings Call Highlights: Promising Progress in ...
Design Therapeutics Inc (DSGN) reports encouraging advancements in their RESTORE-FA trial, with key data expected later this year, despite early-stage challenges.
Design Therapeutics Q1 Earnings Call Highlights
Design Therapeutics (NASDAQ:DSGN) outlined its strategy and trial design for DT-216 in Friedreich’s ataxia (FA), emphasizing that its ongoing RESTORE-FA multiple ascending dose study is intended to determine whether the therapy can meaningfully increase endogenous frataxin levels and help define a p
We Think Design Therapeutics (NASDAQ:DSGN) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Design Therapeutics...
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program
Design Therapeutics (NASDAQ:DSGN) outlined its near-term clinical priorities and key upcoming data readouts during a conference discussion with Leerink Partners’ Joe Schwartz, featuring comments from CEO Pratik Shah. The conversation focused on the company’s Friedreich’s ataxia (FA) program, ongoing
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference
Design Therapeutics (NASDAQ:DSGN) outlined progress across three clinical-stage programs and discussed upcoming catalysts during an Oppenheimer healthcare conference presentation led by CEO Pratik Shah. The company is developing what it describes as “small molecule genetic medicines” designed to mod